Izzedine H - Search Results

1

QT interval prolongation among patients treated with angiogenesis inhibitors.

Ederhy S, Cohen A, Dufaitre G, Izzedine H, Massard C, Meuleman C, Besse B, Berthelot E, Boccara F, Soria JC. Ederhy S, et al. Among authors: izzedine h. Target Oncol. 2009 Apr;4(2):89-97. doi: 10.1007/s11523-009-0111-3. Epub 2009 May 6. Target Oncol. 2009. PMID: 19418112 Review.

2

Management of hypertension in angiogenesis inhibitor-treated patients.

Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP. Izzedine H, et al. Ann Oncol. 2009 May;20(5):807-15. doi: 10.1093/annonc/mdn713. Epub 2009 Jan 15. Ann Oncol. 2009. PMID: 19150949 Free article. Review.

3

Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report.

Gombos A, Izzedine H, Besse B, Massard C, Brocheriou I, Bahleda R, Soria JC. Gombos A, et al. Among authors: izzedine h. Invest New Drugs. 2010 Feb;28(1):102-5. doi: 10.1007/s10637-009-9247-3. Epub 2009 Apr 3. Invest New Drugs. 2010. PMID: 19343274

4

Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial.

Bahleda R, Massard C, Soria JC, Izzedine H, Cohen A, Ederhy S. Bahleda R, et al. Among authors: izzedine h. Invest New Drugs. 2010 Jun;28(3):350-2. doi: 10.1007/s10637-009-9252-6. Epub 2009 Apr 25. Invest New Drugs. 2010. PMID: 19396400

5

Reversible cardiogenic shock following 5-fluorouracil infusion.

Ferté C, Gomez Roca C, Loriot Y, Bahleda R, Moldovan C, Cohen A, Izzedine H, Soria JC, Ederhy S. Ferté C, et al. Among authors: izzedine h. Invest New Drugs. 2010 Aug;28(4):531-3. doi: 10.1007/s10637-009-9271-3. Epub 2009 Jun 5. Invest New Drugs. 2010. PMID: 19499187

6

Thrombotic microangiopathy related to anti-VEGF agents: intensive versus conservative treatment?

Izzedine H, Sène D, Hadoux J, Gharbi C, Bourry E, Massard C, Soria JC. Izzedine H, et al. Ann Oncol. 2011 Feb;22(2):487-90. doi: 10.1093/annonc/mdq743. Ann Oncol. 2011. PMID: 21278225 Free article. Clinical Trial. No abstract available.

7

Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists.

Ederhy S, Izzedine H, Massard C, Dufaitre G, Spano JP, Milano G, Meuleman C, Besse B, Boccara F, Kahyat D, Cohen A, Soria JC. Ederhy S, et al. Among authors: izzedine h. Crit Rev Oncol Hematol. 2011 Dec;80(3):369-79. doi: 10.1016/j.critrevonc.2011.01.009. Epub 2011 Feb 16. Crit Rev Oncol Hematol. 2011. PMID: 21330149 Review.

8

Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials.

Levy A, Albiges-Sauvin L, Massard C, Izzedine H, Ederhy S, Bahleda R, Gomez-Roca C, Chargari C, Brocheriou-Spelle I, Soria JC. Levy A, et al. Among authors: izzedine h. Invest New Drugs. 2012 Jun;30(3):1116-20. doi: 10.1007/s10637-011-9671-z. Epub 2011 Apr 21. Invest New Drugs. 2012. PMID: 21509469 Clinical Trial.

9

Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.

Izzedine H, Escudier B, Rouvier P, Gueutin V, Varga A, Bahleda R, Soria JC. Izzedine H, et al. Ann Oncol. 2013 Sep;24(9):2421-5. doi: 10.1093/annonc/mdt233. Epub 2013 Jun 24. Ann Oncol. 2013. PMID: 23798615 Free article.

10

Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.

Izzedine H, Mangier M, Ory V, Zhang SY, Sendeyo K, Bouachi K, Audard V, Péchoux C, Soria JC, Massard C, Bahleda R, Bourry E, Khayat D, Baumelou A, Lang P, Ollero M, Pawlak A, Sahali D. Izzedine H, et al. Kidney Int. 2014 Feb;85(2):457-70. doi: 10.1038/ki.2013.344. Epub 2013 Sep 25. Kidney Int. 2014. PMID: 24067439 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

268 results

Search Page